ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-18Q7541
Home | Market Reports | Health| Health Conditions| Cancer
Global Kidney Cancer and Renal Cell Carcinoma RCC Drugs Market Insights and Forecast to 2028
BUY CHAPTERS

Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Research Report 2025

Code: QYRE-Auto-18Q7541
Report
July 2025
Pages:71
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Active Biotech Ab
Amgen Inc
Bayer
Cipla Ltd
Roche Holding AG
GlaxoSmithKline PLC
Novartis
Pfizer Inc

Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size

The global market for Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs was valued at US$ 5458 million in the year 2024 and is projected to reach a revised size of US$ 6842 million by 2031, growing at a CAGR of 3.3% during the forecast period.

Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market

Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market

Kidney cancer/ renal cell carcinoma (RCC) is among ten most commonly observed cancer these days. It is sixth common cancer observed in men and it is the tenth most common cause of cancer for women.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs.
The Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Report

Report Metric Details
Report Name Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market
Accounted market size in year US$ 5458 million
Forecasted market size in 2031 US$ 6842 million
CAGR 3.3%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Afinitor (Everolimus)
  • Avastin (Bevacizumab)
  • Cabomety (Cabozantinib)
  • Inlyta (Axitinib)
  • Nexavar (Sorafenib)
  • Proleukin (Aldesleukin)
  • Torisel (Temsirolimus)
  • Sutent (Sunitinib)
  • Votrient (Pazopanib)
Segment by Application
  • Hospitals
  • Clinic
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Active Biotech Ab, Amgen, Bayer AG, Cipla Limited, Roche Holding AG, Glaxosmithkline Plc, Novartis Ag, Pfizer, Inc.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market growing?

Ans: The Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market witnessing a CAGR of 3.3% during the forecast period 2025-2031.

What is the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market size in 2031?

Ans: The Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market size in 2031 will be US$ 6842 million.

Who are the main players in the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market report?

Ans: The main players in the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market are Active Biotech Ab, Amgen, Bayer AG, Cipla Limited, Roche Holding AG, Glaxosmithkline Plc, Novartis Ag, Pfizer, Inc.

What are the Application segmentation covered in the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market report?

Ans: The Applications covered in the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market report are Hospitals, Clinic, Others

What are the Type segmentation covered in the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market report?

Ans: The Types covered in the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market report are Afinitor (Everolimus), Avastin (Bevacizumab), Cabomety (Cabozantinib), Inlyta (Axitinib), Nexavar (Sorafenib), Proleukin (Aldesleukin), Torisel (Temsirolimus), Sutent (Sunitinib), Votrient (Pazopanib)

Recommended Reports

Kidney & Renal Drugs

Oncology Therapeutics

Urology & Related

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Afinitor (Everolimus)
1.2.3 Avastin (Bevacizumab)
1.2.4 Cabomety (Cabozantinib)
1.2.5 Inlyta (Axitinib)
1.2.6 Nexavar (Sorafenib)
1.2.7 Proleukin (Aldesleukin)
1.2.8 Torisel (Temsirolimus)
1.2.9 Sutent (Sunitinib)
1.2.10 Votrient (Pazopanib)
1.3 Market by Application
1.3.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Perspective (2020-2031)
2.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Growth Trends by Region
2.2.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Historic Market Size by Region (2020-2025)
2.2.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Region (2026-2031)
2.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Dynamics
2.3.1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Industry Trends
2.3.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Drivers
2.3.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Challenges
2.3.4 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Revenue
3.1.1 Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Revenue (2020-2025)
3.1.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue
3.4 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Concentration Ratio
3.4.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in 2024
3.5 Global Key Players of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Head office and Area Served
3.6 Global Key Players of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs, Product and Application
3.7 Global Key Players of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Breakdown Data by Type
4.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Historic Market Size by Type (2020-2025)
4.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Type (2026-2031)
5 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Breakdown Data by Application
5.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Historic Market Size by Application (2020-2025)
5.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2020-2031)
6.2 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2020-2025)
6.4 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2020-2031)
7.2 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2020-2025)
7.4 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2020-2031)
8.2 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2020-2031)
9.2 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2020-2025)
9.4 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2020-2031)
10.2 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Active Biotech Ab
11.1.1 Active Biotech Ab Company Details
11.1.2 Active Biotech Ab Business Overview
11.1.3 Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.1.4 Active Biotech Ab Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2020-2025)
11.1.5 Active Biotech Ab Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.2.4 Amgen Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2020-2025)
11.2.5 Amgen Recent Development
11.3 Bayer AG
11.3.1 Bayer AG Company Details
11.3.2 Bayer AG Business Overview
11.3.3 Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.3.4 Bayer AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2020-2025)
11.3.5 Bayer AG Recent Development
11.4 Cipla Limited
11.4.1 Cipla Limited Company Details
11.4.2 Cipla Limited Business Overview
11.4.3 Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.4.4 Cipla Limited Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2020-2025)
11.4.5 Cipla Limited Recent Development
11.5 Roche Holding AG
11.5.1 Roche Holding AG Company Details
11.5.2 Roche Holding AG Business Overview
11.5.3 Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.5.4 Roche Holding AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2020-2025)
11.5.5 Roche Holding AG Recent Development
11.6 Glaxosmithkline Plc
11.6.1 Glaxosmithkline Plc Company Details
11.6.2 Glaxosmithkline Plc Business Overview
11.6.3 Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.6.4 Glaxosmithkline Plc Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2020-2025)
11.6.5 Glaxosmithkline Plc Recent Development
11.7 Novartis Ag
11.7.1 Novartis Ag Company Details
11.7.2 Novartis Ag Business Overview
11.7.3 Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.7.4 Novartis Ag Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2020-2025)
11.7.5 Novartis Ag Recent Development
11.8 Pfizer, Inc.
11.8.1 Pfizer, Inc. Company Details
11.8.2 Pfizer, Inc. Business Overview
11.8.3 Pfizer, Inc. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.8.4 Pfizer, Inc. Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2020-2025)
11.8.5 Pfizer, Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Active Biotech Ab
Amgen Inc
Bayer
Cipla Ltd
Roche Holding AG
GlaxoSmithKline PLC
Novartis
Pfizer Inc
List of Tables
 Table 1. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Afinitor (Everolimus)
 Table 3. Key Players of Avastin (Bevacizumab)
 Table 4. Key Players of Cabomety (Cabozantinib)
 Table 5. Key Players of Inlyta (Axitinib)
 Table 6. Key Players of Nexavar (Sorafenib)
 Table 7. Key Players of Proleukin (Aldesleukin)
 Table 8. Key Players of Torisel (Temsirolimus)
 Table 9. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 10. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 11. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region (2020-2025) & (US$ Million)
 Table 12. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Region (2020-2025)
 Table 13. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 14. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Region (2026-2031)
 Table 15. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Trends
 Table 16. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Drivers
 Table 17. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Challenges
 Table 18. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Restraints
 Table 19. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue by Players (2020-2025) & (US$ Million)
 Table 20. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Players (2020-2025)
 Table 21. Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs as of 2024)
 Table 22. Ranking of Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Companies by Revenue (US$ Million) in 2024
 Table 23. Global 5 Largest Players Market Share by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (CR5 and HHI) & (2020-2025)
 Table 24. Global Key Players of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs, Headquarters and Area Served
 Table 25. Global Key Players of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs, Product and Application
 Table 26. Global Key Players of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs, Date of Enter into This Industry
 Table 27. Mergers & Acquisitions, Expansion Plans
 Table 28. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2020-2025) & (US$ Million)
 Table 29. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Type (2020-2025)
 Table 30. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 31. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Type (2026-2031)
 Table 32. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2020-2025) & (US$ Million)
 Table 33. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Application (2020-2025)
 Table 34. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 35. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Application (2026-2031)
 Table 36. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 37. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 38. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 39. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 40. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 41. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 42. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 43. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region (2020-2025) & (US$ Million)
 Table 44. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region (2026-2031) & (US$ Million)
 Table 45. Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 46. Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 47. Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 48. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 49. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 50. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 51. Active Biotech Ab Company Details
 Table 52. Active Biotech Ab Business Overview
 Table 53. Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
 Table 54. Active Biotech Ab Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2020-2025) & (US$ Million)
 Table 55. Active Biotech Ab Recent Development
 Table 56. Amgen Company Details
 Table 57. Amgen Business Overview
 Table 58. Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
 Table 59. Amgen Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2020-2025) & (US$ Million)
 Table 60. Amgen Recent Development
 Table 61. Bayer AG Company Details
 Table 62. Bayer AG Business Overview
 Table 63. Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
 Table 64. Bayer AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2020-2025) & (US$ Million)
 Table 65. Bayer AG Recent Development
 Table 66. Cipla Limited Company Details
 Table 67. Cipla Limited Business Overview
 Table 68. Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
 Table 69. Cipla Limited Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2020-2025) & (US$ Million)
 Table 70. Cipla Limited Recent Development
 Table 71. Roche Holding AG Company Details
 Table 72. Roche Holding AG Business Overview
 Table 73. Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
 Table 74. Roche Holding AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2020-2025) & (US$ Million)
 Table 75. Roche Holding AG Recent Development
 Table 76. Glaxosmithkline Plc Company Details
 Table 77. Glaxosmithkline Plc Business Overview
 Table 78. Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
 Table 79. Glaxosmithkline Plc Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2020-2025) & (US$ Million)
 Table 80. Glaxosmithkline Plc Recent Development
 Table 81. Novartis Ag Company Details
 Table 82. Novartis Ag Business Overview
 Table 83. Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
 Table 84. Novartis Ag Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2020-2025) & (US$ Million)
 Table 85. Novartis Ag Recent Development
 Table 86. Pfizer, Inc. Company Details
 Table 87. Pfizer, Inc. Business Overview
 Table 88. Pfizer, Inc. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
 Table 89. Pfizer, Inc. Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2020-2025) & (US$ Million)
 Table 90. Pfizer, Inc. Recent Development
 Table 91. Research Programs/Design for This Report
 Table 92. Key Data Information from Secondary Sources
 Table 93. Key Data Information from Primary Sources
 Table 94. Authors List of This Report


List of Figures
 Figure 1. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Picture
 Figure 2. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type: 2024 VS 2031
 Figure 4. Afinitor (Everolimus) Features
 Figure 5. Avastin (Bevacizumab) Features
 Figure 6. Cabomety (Cabozantinib) Features
 Figure 7. Inlyta (Axitinib) Features
 Figure 8. Nexavar (Sorafenib) Features
 Figure 9. Proleukin (Aldesleukin) Features
 Figure 10. Torisel (Temsirolimus) Features
 Figure 11. Sutent (Sunitinib) Features
 Figure 12. Votrient (Pazopanib) Features
 Figure 13. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2020-2031) & (US$ Million)
 Figure 14. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application: 2024 VS 2031
 Figure 15. Hospitals Case Studies
 Figure 16. Clinic Case Studies
 Figure 17. Others Case Studies
 Figure 18. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Report Years Considered
 Figure 19. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 20. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 21. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Region: 2024 VS 2031
 Figure 22. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Players in 2024
 Figure 23. Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs as of 2024)
 Figure 24. The Top 10 and 5 Players Market Share by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in 2024
 Figure 25. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Country (2020-2031)
 Figure 27. United States Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Canada Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Country (2020-2031)
 Figure 31. Germany Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. France Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. U.K. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Italy Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Russia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Nordic Countries Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Region (2020-2031)
 Figure 39. China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. South Korea Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Australia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Country (2020-2031)
 Figure 47. Mexico Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Brazil Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Country (2020-2031)
 Figure 51. Turkey Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 52. Saudi Arabia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 53. UAE Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 54. Active Biotech Ab Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2020-2025)
 Figure 55. Amgen Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2020-2025)
 Figure 56. Bayer AG Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2020-2025)
 Figure 57. Cipla Limited Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2020-2025)
 Figure 58. Roche Holding AG Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2020-2025)
 Figure 59. Glaxosmithkline Plc Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2020-2025)
 Figure 60. Novartis Ag Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2020-2025)
 Figure 61. Pfizer, Inc. Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2020-2025)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

Global Kidney Cancer Therapeutics and Diagnostics Market Insights Forecast to 2030
Renal Cell Cancer Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Cancer Drug Therapy Market Insights Forecast to 2030
Kidney Cancer Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Kidney Cancer Drugs Market Research Report 2024
Kidney Cancer Diagnostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Renal Cell Cacinoma Drugs Market Research Report 2024
Renal Cell Carcinoma Therapy Devices Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Advanced Renal Cell Carcinoma Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Urological Cancer Therapeutics Drugs Market Research Report 2024
Renal Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Kidney Cancer Therapy Market Research Report 2024
Global Kidney Cancer Molecular Diagnostics Market Research Report 2024
Global Kidney Medicine Market Insights Forecast to 2030
Global Kidney Cancer Therapeutics Market Research Report 2025
Global Adrenocortical Carcinoma Drugs Market Insights Forecast to 2030
Global Kidney Cancer Targeted Therapy Market Research Report 2025
Global Kidney Cancer Market Research Report 2025
Global Non small Cell Lung Cancer Drugs Market Insights Forecast to 2030
Global Kidney Cancer or Renal Cancer Market Research Report 2024

RELATED REPORTS

Global Radioactive Iodine Ablation Therapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9U20281
Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global AI Contouring Software for Radiotherapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-32T20006
Thu Nov 27 00:00:00 UTC 2025

Add to Cart

Global Cell Senescence β-Galactosidase Staining Kit Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-0Q20500
Thu Nov 27 00:00:00 UTC 2025

Add to Cart

Global Kinase Inhibitors For Cancer Treatment Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-18V16958
Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions